Carole Nuechterlein, J.D., has served as a member of our board of directors since August 2018. Ms. Nuechterlein was the Head of the Roche Venture Fund from 2001 until her retirement in April 2026.  Ms. Nuechterlein was responsible for RVF’s investments in, among others, Alios, Ambrx, Anadys, AveXis, Enthera, Pharmasset,and SpliceBio.  She currently serves on the board ofFreenome Holdings, Inc. In addition to numerous private companies, Ms. Nuechterlein previously served as a member of the board of directors of AveXis,Inc., Entrada Therapeutics, Inc., and Millendo Therapeutics. Prior to heading RVF, Ms. Nuechterlein was General Counsel of SangStat, Inc.  She received a B.A. in English and Humanities from Valparaiso University and a J.D. from the University of Michigan.In addition to numerous private companies, Ms. Nuechterlein previously served as a member of the board of directors of AveXis,Inc., Entrada Therapeutics, Inc., and Millendo Therapeutics. Prior to heading RVF, Ms. Nuechterlein was General Counsel of SangStat, Inc.  She received a B.A. in English and Humanities from Valparaiso University and a J.D. from the University of Michigan.